辛伐他汀联合非诺贝特治疗混合性高脂血症63例疗效观察  

Clinical effect of simvastatin combined with fenofibrate in the treatment of hyperlipidemia.

作　　者：何名梅 苏国生[2] 劳炳焕 

机构地区：[1]北流市妇幼保健院,广西北流537400 [2]南宁市第四人民医院,广西南宁530023 [3]合浦县红十字会医院,广西合浦536100

出　　处：《海南医学》2013年第3期332-334,共3页Hainan Medical Journal

基　　金：2011年北海市科学研究与技术开发计划项目(编号:北科合字201107002)

摘　　要：目的观察辛伐他汀联合非诺贝特治疗混合性高脂血症的疗效及安全性。方法 126例混合性高脂血症患者随机分为两组各63例,观察组每天清晨口服非诺贝特微粒化胶囊100mg,夜间口服辛伐他汀10mg,对照组每晚顿服辛伐他汀20mg,两组疗程均为12周。观察两组治疗前后主要血脂参数的变化率、疗效、达标率及不良反应。结果治疗后观察组总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)水平均低于对照组,t分别为6.3048、6.6946、31.7681、6.2810,P均<0.01,差异有统计学意义;观察组总有效率高于对照组,χ2=6.98,P<0.01,差异有统计学意义;观察组LDL-C、TG、TC3项达标均高于对照组,χ2分别为4.67、6.30、5.03,P均<0.05,差异有统计学意义;观察组丙氨酸氨基转移酶(ALT)轻度升高2例,对照组3例,均小于正常值3倍,差异无统计学意义;两组肌酸激酶(CK)无明显变化,未出现肌病症状。结论辛伐他汀联合非诺贝特治疗混合性高脂血症临床效果明显,具有良好的安全性。Objective To observe the clinical effect and safety of simvastatin combined with fenofibrate in the treatment of mixed hyperlipidemia. Methods One hundred and twenty-six patients with mixed hyperlipidemia were randomly divided into two groups, each with 63 cases. Patients in the observation group took orally micronised fenofibrate 100 mg in the morning and simvastatin 10 mg at night, while those in the control group received simvas-tatin 20 mg at night. All the patients were treated for 12 weeks. The rate of change of the major lipid parameters be-fore and after treatment was observed, as well as the clinical efficacy, incidence of compliances and adverse reactions. Results For lipid parameters, the levels of total cholesterol （TC）, low-density lipoprotein cholesterol （LDL-C）, triglyc-erides （TG）, high density lipoprotein cholesterol （HDL-C） were significantly lower in the observation group than the control group （t=6.304 8, 6.694 6, 3!.768 1, 6.281 0, respectively, P〈0.01）. In the comparison of clinical efficacy, the to-tal effective rate in the observation group was significantly higher than that in the control group （X^2=6.98, P〈0.01）. The general ratio of reaching standard for LDL-C, TG, TC were significantly higher in the observation group （X^2=4.67, 6.30, 5.03, P〈0.05）. Increased alanine amino transferase （ALT） levels were found in two patients of the observation group and three patients of the control group, lower than 3 times of the normal value, with no statistically significant difference. The two groups showed no significant difference in ereatine kinase （CK）, with no symptoms of myopa- thy. Conclusion Simvastatin combined with fenofibrate is quite effective and safe for treating mixed hyperlipidemia.

关 键 词：辛伐他汀 非诺贝特 高脂血症 

分 类 号：R589.2[医药卫生—内分泌]